Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
483.96
-10.65 (-2.15%)
Nov 14, 2024, 4:00 PM EST - Market closed
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trikafta and Kaftrio Revenue | 9.50B | 9.29B | 8.94B | 8.63B | 8.37B | 8.02B | 7.69B | 7.36B | |||||||||||
| Trikafta and Kaftrio Revenue Growth | 13.46% | 15.77% | 16.36% | 17.33% | 21.24% | 28.03% | 34.92% | 44.41% | |||||||||||
| Kalydeco Revenue | 475.50M | 499.20M | 525.80M | 539.20M | 553.20M | 569.30M | 592.30M | 636.90M | |||||||||||
| Kalydeco Revenue Growth | -14.05% | -12.31% | -11.23% | -15.34% | -19.15% | -21.52% | -21.74% | -17.99% | |||||||||||
| Orkambi Revenue | 326.00M | 392.60M | 475.80M | 501.10M | 510.70M | 547.30M | 585.60M | 685.00M | |||||||||||
| Orkambi Revenue Growth | -36.17% | -28.27% | -18.75% | -26.85% | -33.81% | -34.82% | -33.54% | -23.21% | |||||||||||
| Symdeko and Semkevi Revenue | 123.00M | 129.50M | 134.30M | 145.80M | 180.00M | 226.10M | 269.30M | 360.10M | |||||||||||
| Symdeko and Semkevi Revenue Growth | -31.67% | -42.72% | -50.13% | -59.51% | -57.18% | -51.64% | -50.34% | -37.97% |
Revenue by Geography
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US Revenue | 6.26B | 6.16B | 6.04B | 5.93B | 5.83B | 5.73B | 5.70B | 5.63B | |||||||||||
| US Revenue Growth | 7.47% | 7.35% | 5.98% | 5.21% | 4.81% | 6.16% | 7.79% | 10.47% | |||||||||||
| Europe Revenue | 3.28B | 3.27B | 3.11B | 3.06B | 3.02B | 2.88B | 2.71B | 2.61B | |||||||||||
| Europe Revenue Growth | 8.30% | 13.50% | 14.91% | 17.34% | 26.21% | 30.92% | 37.13% | 49.68% | |||||||||||
| Other Revenue | 798.40M | 759.30M | 719.80M | 667.10M | 652.50M | 592.70M | 525.90M | 459.10M | |||||||||||
| Other Revenue Growth | 22.36% | 28.11% | 36.87% | 45.31% | 65.90% | 71.65% | 67.91% | 60.61% |
Operating Expense Breakdown
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acquired In-Process Research and Development | 4.60B | 256.80M | 527.10M | 531.90M | 509.20M | 460.60M | 115.50M | 221.10M | |||||||||||
| Acquired In-Process Research and Development Growth | 802.47% | -44.25% | 356.36% | 140.57% | 132.72% | -58.70% | -89.63% | -77.56% | |||||||||||
| Research and Development | 3.39B | 3.21B | 3.16B | 3.03B | 2.87B | 2.68B | 2.54B | 2.41B | |||||||||||
| Research and Development Growth | 18.24% | 19.67% | 24.51% | 25.71% | 28.34% | 28.75% | 31.09% | 31.23% | |||||||||||
| Selling, General, and Administrative | 1.35B | 1.24B | 1.14B | 1.03B | 1.02B | 970.60M | 944.70M | 995.50M | |||||||||||
| Selling, General, and Administrative Growth | 32.41% | 27.57% | 20.31% | 3.96% | 7.50% | 4.79% | 12.45% | 35.67% | |||||||||||
| Change in Value of Contingent Consideration | -48.70M | -49.80M | -51.60M | 500.00K | -3.30M | -51.90M | -57.50M | -61.30M |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.